for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ImmuCell Corporation

ICCC.OQ

Latest Trade

5.73USD

Change

-0.05(-0.87%)

Volume

316

Today's Range

5.73

 - 

5.79

52 Week Range

5.15

 - 

9.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.78
Open
5.79
Volume
316
3M AVG Volume
0.10
Today's High
5.79
Today's Low
5.73
52 Week High
9.29
52 Week Low
5.15
Shares Out (MIL)
7.21
Market Cap (MIL)
41.67
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

ImmuCell Enters Into Lease Agreement For Facility To Expand First Defense Production Capacity

ImmuCell Announces An Agreement Covering The Formulation And Aseptic Filling Of Syringes For Re-Tain

ImmuCell Receives FDA Response To First CMC Submission For Re-Tain

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

Industry

Biotechnology & Drugs

Contact Info

56 Evergreen Dr

+1.207.8782770

http://www.immucell.com/

Executive Leadership

David Scott Tomsche

Independent Chairman of the Board

Michael F. Brigham

President, Chief Executive Officer, Treasurer, Secretary, Director

Bobbi Jo Brockmann

Vice President - Sales and Marketing, Director

Elizabeth Luttrell Williams

Vice President - Manufacturing Operations

David S. Cunningham

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
3.41
Price To Book (MRQ)
1.41
Price To Cash Flow (TTM)
137.22
Total Debt To Equity (MRQ)
29.84
LT Debt To Equity (MRQ)
26.98
Return on Investment (TTM)
-5.17
Return on Equity (TTM)
-4.95

Latest News

BRIEF-ImmuCell Announces Q4 Loss Per Share $0.04

* IMMUCELL ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017

BRIEF-ImmuCell Appoints Two New Members To Its Board Of Directors

* IMMUCELL APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

BRIEF-ImmuCell Corp Announces Pricing Of $3 Mln Public Offering Of Common Shares

* IMMUCELL CORPORATION ANNOUNCES PRICING OF $3 MILLION PUBLIC OFFERING OF COMMON SHARES

BRIEF-Immucell Q3 loss per share $0.07

* Immucell announces financial results for third quarter of 2017

BRIEF-ImmuCell announces expansion of sales and marketing team

* ImmuCell Corp - during Q4 of 2017, company expects to achieve regulatory approval of First Defense Tri-Shield

BRIEF-ImmuCell Q2 loss per share $0.05

* ImmuCell announces financial results for second quarter of 2017

BRIEF-Immucell enters into amendment to agreement with Plas-Pak Industries

* On July 24, co entered into amendment to agreement with Plas-Pak Industries of Norwich, Connecticut, originally dated as of January 4, 2010

BRIEF-Immucell Q1 earnings per share $0.12

* Q1 earnings per share $0.12 Source text (http://bit.ly/2r6XkDr) Further company coverage:

BRIEF-ImmuCell says secures $2 million in debt financing

* ImmuCell secures $2 million in debt financing Source text for Eikon: Further company coverage:

BRIEF-Immucell Q4 sales fell 18 pct

* Q4 sales fell 18 percent to $2.2 million Source text for Eikon: Further company coverage:

BRIEF-Immucell files for sale of up to 659,880 shares of co's common stock

* Files for sale of up to 659,880 shares of co's common stock by selling stockholders - sec filing

BRIEF-ImmuCell to raise $3.5 mln in private placement

* Says co agreed to sell an aggregate total of 659,880 shares of common stock at a price of $5.25 per share to outside investors

BRIEF-Immucell Corp sees FDA approval for Mast Out in 2019

* Immucell Corp - U.S. FDA approval for co's product Mast Out anticipated in 2019, allowing for two, six-month reviews of cmc technical section by FDA Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up